Avatrombopag
Back to searchMolecule Structure
Scientific Name
Avatrombopag
Description of the Drug
Avatrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11995
http://www.drugbank.ca/drugs/DB11995
Brand Name(s)
Not Available
Company Owner(s)
Akarx Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Thrombopoietin receptor | SINGLE PROTEIN | AGONIST | CHEMBL1864 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL289354 | ||
| Human Metabolome Database | HMDB0248737 | ||
| DrugBank | DB11995 | ||
| PubChem: Thomson Pharma | 14814613 | ||
| PubChem | 9852519 | ||
| Nikkaji | J3.032.732B | ||
| EPA CompTox Dashboard | DTXSID30205667 | ||
| DrugCentral | 5285 | ||
| ChemicalBook | CB72522099 | ||
| Guide to Pharmacology | 9953 | ||
| rxnorm | AVATROMBOPAG | AVATROMBOPAG MALEATE | DOPTELET |
| ZINC | ZINC000072190218 |
